Literature DB >> 8592246

Angiotensin converting enzyme inhibitors in hypertension: potential problems.

T F Antonios1, G A MacGregor.   

Abstract

AIM: To review potential problems associated with the use of angiotensin converting enzyme (ACE) inhibitors in the treatment of patients with hypertension. PHYSIOLOGICAL PROBLEMS: ACE inhibitors cause a drop in blood pressure depending on the circulating level of angiotensin II. This may be a problem in patients with severe congestive heart failure, so that it is important to monitor the effect of the ACE inhibitor in this group. Hyperkalaemia can develop in patients with severe renal impairment and potassium plasma levels should be monitored. Renal impairment is another potential problem and in hypertensive patients renal function should be measured before, and a few weeks after, starting treatment. This is especially important when there is any possibility of fibromuscular hyperplasia or atheroscerotic renal artery stenosis. NON-PHYSIOLOGICAL PROBLEM: In addition to a cough, which is the most common problem, skin rashes, loss of taste, haematological effects and angioneurotic oedema are also encountered. The incidence of a cough with most ACE inhibitors is 5-10%.
CONCLUSIONS: compared to other antihypertensive drugs, ACE inhibitors have the major advantage of being well tolerated by most patients with few side effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592246     DOI: 10.1097/00004872-199509003-00003

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  11 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

2.  Spectrum of use for the angiotensin-receptor blocking drugs.

Authors:  M E Fabiani; C I Johnston
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 3.  Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension.

Authors:  A J Wagstaff; R Davis; D McTavish
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

4.  Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide.

Authors:  Mohd Akif; Sylva L Schwager; Colin S Anthony; Bertrand Czarny; Fabrice Beau; Vincent Dive; Edward D Sturrock; K Ravi Acharya
Journal:  Biochem J       Date:  2011-05-15       Impact factor: 3.857

5.  Optimization of hydrolysis conditions for the production of angiotensin-I converting enzyme-inhibitory peptides and isolation of a novel peptide from lizard fish (Saurida elongata) muscle protein hydrolysate.

Authors:  Shanguang Wu; Jianhua Sun; Zhangfa Tong; Xiongdiao Lan; Zhongxing Zhao; Dankui Liao
Journal:  Mar Drugs       Date:  2012-05-18       Impact factor: 6.085

6.  Angiotensin I-converting enzyme inhibitor derived from cross-linked oyster protein.

Authors:  Cheng-Liang Xie; Jin-Soo Kim; Jong-Myung Ha; Se-Young Choung; Yeung-Joon Choi
Journal:  Biomed Res Int       Date:  2014-07-23       Impact factor: 3.411

7.  Design, Synthesis and Evaluation of Novel 2-Hydroxypyrrolobenzodiazepine-5,11-dione Analogues as Potent Angiotensin Converting Enzyme (ACE) Inhibitors.

Authors:  Ying Sun; Yujun Bai; Xirui He; Yajun Bai; Pei Liu; Zefeng Zhao; Xufei Chen; Xiaohui Zheng
Journal:  Molecules       Date:  2017-11-03       Impact factor: 4.411

8.  A Novel Antihypertensive Derived from Adlay (Coix larchryma-jobi L. var. ma-yuen Stapf) Glutelin.

Authors:  Bin Li; Liansheng Qiao; Lingling Li; Yanling Zhang; Kai Li; Lingzhi Wang; Yanjiang Qiao
Journal:  Molecules       Date:  2017-01-13       Impact factor: 4.411

9.  Angiotensin-I-Converting Enzyme Inhibitory Activity of Coumarins from Angelica decursiva.

Authors:  Md Yousof Ali; Su Hui Seong; Hyun Ah Jung; Jae Sue Choi
Journal:  Molecules       Date:  2019-10-31       Impact factor: 4.411

10.  Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.

Authors:  Geoffrey Masuyer; Mohd Akif; Bertrand Czarny; Fabrice Beau; Sylva L U Schwager; Edward D Sturrock; R Elwyn Isaac; Vincent Dive; K Ravi Acharya
Journal:  FEBS J       Date:  2013-12-24       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.